Further, the lower cost of these drugs as compared to the patented biologics, the increasing encumbrance to curb healthcare costs globally, increasing nationwide government initiatives, and the strong pipeline for the biosimilar drugs is expected to fuel the biosimilars industry. On the other hand, high manufacturing complexities and costs, stringent regulatory requirements in countries and operational challenges are restricting the growth of the biosimilars market.
Key Highlights of the Report: Biosimilars Market - By Product Type - erythropoietin (EPO) captures maximum share of the global bioismilars market. The Granulocyte- Colony Stimulating Factor (G-CSF) market is expected to cross US$ 6 Billion mark by 2021. The Human Growth Hormone (HGH) biosimilars market is expected to grow with a double digit CAGR during the period 2016 - 2021. The monoclonal antibody is expected to show the highest growth rate during the period 2016 - 2021. The insulin and interferon product segment each accounted for single digit share of the global biosimilars market respectively in 2015.
Biosimilars Market - By Applications - Among various application segments of biosimilar market, blood disorders and oncology together accounted for over 55% share of the global biosimilars market in 2015. Growth hormone deficiencies application is expected to show double digit CAGR during the period 2016 - 2021. The chronic and autoimmune disorders captured XX% share of the biosmilars market in 2015.
Biosimilars Market - By Country - The market for biosimilars in the U.S. has gained momentum after the launch of Novartis' Zarxio in September 2015. In the European countries, Germany is at the forefront with around XX% share of the biosimilars market in 2015 followed by France with XX% share in the same year. China accounted for XX% share of the global biosimilar market in 2015. India is seen as a key player in the biosimilar space with an exceptionally high number of approvals granted in the last decade compared to the global average. South Korea captured XX% of the global biosimilar market in 2015 being closely followed by Brazil with XX% share in the same year.
Global Biosimilars Company Analysis - 13 Companies Covered: Biocad, Celltrion Inc., Dong-A Socio Group, Pfizer Inc., Intas Pharmaceuticals Ltd., Sandoz International GmbH - A Novartis Company, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Amgen Inc., Biocon, Dr. Reddy's Laboratories, Mylan & Merck KGaA
5 Applications Covered include Oncology, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders & Other Applications. 16 Countries/Regions Covered include United States, Canada, Argentina, Germany, France, Italy, Spain, United Kingdom, China, Japan, India, South Korea, Australia, Brazil, Mexico & Rest of the World.
Other Related Reports on Biosimilars Market:
Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016 : Report provides an insight on Insulin Biosimilars that are under development for Type 1 and Type 2 Diabetes with an insight on the Epidemiology of the disease. It provides detailed information on the 11 Insulin Biosimilar that are in pipeline. It analyses Insulin Biosimilar industry and discusses the key market trends, major players, market assessment of 6 marketed insulin and the types of insulin with the length activity available in market. Report provides an update on the recent collaborations occurring in the insulin biosimilar market and the companies looking for partnership for the same. Comprehensive table of contents and more for this research is available at http://www.marketreportsonline.com/447103-toc.html .
Market Reports Online comprises of an online library of 250,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Contact Us: Ritesh Tiwari
2nd floor, Metropole, Next to Inox theatre,
Bund garden road, Pune-411001
Tel: + 1 888 391 5441